Grants and Contracts Details
We hypothesize that interleukin 1 receptor antagonist (IL-1Ra) administered intra-articularly during the early phases of acute ACL injury will provide symptomatic pain relief and decrease synovial fluid inflammatory markers and cartilage degradation.
|Effective start/end date||3/1/12 → 2/28/13|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.